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www.sciencedirect.comPrimary open-angle glaucoma (POAG), a leading cause of
blindness worldwide, is a heterogeneous disease that
uniquely presents and progresses differently within geneti-
cally distinct populations. As the reduction of intraocular
pressure (IOP), the only currently approved method of ther-
apy, has failed to fully arrest the disease, it is important to
increase awareness of population-specific risk factors and
develop improved management plans. Although POAG has
been extensively studied in Asian, European, and recently
African descent populations, it remains poorly characterized
in patients of Middle Eastern descent (MED).
Specifically, POAG has been shown to more dispropor-
tionately affect people of Asian and African descent com-
pared to those of European descent. A key finding in Asian
populations is the exceptionally high proportion of normal-
tension glaucoma (NTG).1 A recent review by Huck et al.
highlighted that among POAG patients; African decent
patients have larger cup-to-disc ratios (CDR), thinner cor-
neas, a greater proportion of systemic vascular diseases,
and possibly higher IOP levels when compared to European
descent patients.2 Our group recently demonstrated that
reductions in retrobulbar and retinal capillary blood flow in
African decent POAG patients are strongly correlated with
glaucomatous structural changes in the optic nerve head
and reduced macular thickness compared to their European
decent counterparts.3
Together, these findings highlight the importance of
investigating differences in POAG across different popula-
tions to provide improved approaches to disease manage-
ment. We believe there is currently a significant lack of
knowledge of such clinically relevant considerations in
MED populations. A study evaluating IOP in Iran found a
3.2% prevalence of POAG, and among POAG patients
53% were high-tension and 47% were NTG.4 The higher
than expected percentage of NTG in this sample mirrors
Asian POAG patients, and suggests that screening with
IOP may be less effective in these populations. However,
this study was limited to Iran and very few distinguishing
studies have been performed in MED populations. Mousa
et al. showed that total antioxidant status was significantly
decreased and associated with worse POAG indices in
Saudi Arabian patients.5 A genetic review of POAG
described that antioxidant glutathione S-transferase geno-
types GSTT1 and GSTM1 are strongly associated with
POAG across ethnicities, including MED patients.6 In con-trast, several loci do not appear to contribute to POAG in
patients of MED as they do in other groups. Taken
together, these potential genetic and pathophysiologic vari-
ations in MED patients suggest the possibility of subsequent
clinical differences, and therefore warrant further explo-
ration. Significant data is missing detailing the prevalence,
incidence, and progression of POAG in MED populations,
as well as a comparative understanding of specific clinical
risk factors including CDR, corneal thickness, optic disc size,
ocular blood flow, and co-morbidities.
Distinctive genetic and physiological mechanisms differ
among population groups and contribute to diverse POAG
risk factor profiles, prognosis, and responses to treatments.
To date, there is a disparity of data and understanding of risk
in MED POAG patients despite growing MED populations
worldwide. Due to recent findings in POAG patients of Afri-
can descent among others, and specific findings of high
prevalence of NTG and low antioxidant status in MED POAG
patients, we strongly encourage discussion and identification
of specific POAG risk factors in MED populations.Funding
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